Doench JG, Fusi N, Sullender M, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34(2):184-191.
Doench JG, Hartenian E, Graham DB, et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol. 2014;32(12):1262-1267.
Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84-87.
John Doench, Ph.D.
John Doench is associate director of the Genetic Perturbation Platform of the Broad Institute of MIT and Harvard, where he is also an institute scientist. Doench works with a wide variety of research groups across many areas of biology toward understanding how gene dysfunction leads to disease. He has many years of experience in the development and use of functional genomic techniques, first with RNAi and more recently with CRISPR technology for genome-wide loss-of-function screening.
Since joining the Broad Institute in 2009, Doench has engaged in dozens of collaborations centered on functional genomics. He received the Broad Institute Excellence Award in Collaboration in 2013 and was named as the Merkin Institute Fellow in the same year.
Prior to joining the Broad Institute, Doench completed postdoctoral research with Ed Harlow at Harvard Medical School. He holds a Ph.D. in biology from MIT and a B.A. in history from Hamilton College.